Pesquisar
Innate Pharma SA
IPHAAdicionar à lista de desejos
2.180USD
-0.355-14.00%
Fechamento 08-14 16:00（ET）Cotações atrasadas em 15 min
202.21MValor de mercado
PerdaP/L TTM
Mais detalhes de Innate Pharma SA Empresa
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Innate Pharma SA Perfil
Código da empresaIPHA
Nome da EmpresaInnate Pharma SA
Data de listagemOct 31, 2006
CEODickinson (Jonathan Elliot)
Número de funcionários181
Tipo de títulosDepository Receipt
Fim do ano fiscalOct 31
Endereço117 avenue de Luminy
CidadeMARSEILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal13009
Telefone33430303030
Sitehttps://www.innate-pharma.com/
Código da empresaIPHA
Data de listagemOct 31, 2006
CEODickinson (Jonathan Elliot)
Executivos da empresa Innate Pharma SA
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
Chief Compliance and Operations Officer, Interim Head of human Resources, Vice President
--
--
Ms. Odile Laurent
Ms. Odile Laurent
Vice President - Human Resources, Member of the Leadership Team
Vice President - Human Resources, Member of the Leadership Team
--
--
Ms. Pascale Boissel
Ms. Pascale Boissel
Vice Independent Chairman of the Board
Vice Independent Chairman of the Board
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Independent Director, Representative of Bpifrance Participations
Independent Director, Representative of Bpifrance Participations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mrs. Irina Staatz-Granzer, Ph.D.
Mrs. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Director
Independent Director
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Innate Pharma SA?
Os cinco principais acionistas de Innate Pharma SA são: Mr. Gilles Brisson
Quantas instituições possuem ações da Innate Pharma SA (IPHA)?
Em 2026Q1, 22 instituições possuíam ações da Innate Pharma SA, com valor de mercado aproximado de 336.10K, representando 0.37% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 136136.00.